Could be very interesting. CPH appointed Amit Edri as International Business Development Executive in Feb 2018. He had previously been COO of Israel's largest MC company, The Bazelet Group. Israel is reported to already have 30,000 MC patients, and Bazelet were reported to have been supplying about 10,000 of them, so we can assume that Mr. Edri is a major figure in the Israeli MC market.
The post on MJJ about the possibilty of CPH acquiring ESE might not be totally off the mark. Time will tell.
CPH have a lot of very significant developments underway, including the large Mernova MC production facility in Nova Scotia, the proposed acquisition of Kunna Canada and its Colombian subsidiary this month, expansion of the marketing of their QIX10 and QIX50 nutraceuticals and their cannaDOL range, and their anibidiol animal products.
CPH Price at posting:
72.5¢ Sentiment: Buy Disclosure: Held
